Contraception
Volume 81, Issue 6 , Pages 474-480 , June 2010

Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women

  • Carolyn L. Westhoff

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 305 4805; fax: +1 212 305 6438.
    • ,
  • Anupama H. Torgal

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
    • ,
  • Elizabeth R. Mayeda

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
    • ,
  • Malcolm C. Pike

      Affiliations

    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
    • Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • ,
  • Frank Z. Stanczyk

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Received 7 December 2009 ,Revised 7 January 2010 ,Accepted 14 January 2010.

References 

  1. Dinger JC, Cronin M, Mohner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol. 2009;201:e1–e9
  2. Trussell J, Schwarz EB, Guthrie K. Obesity and oral contraceptive pill failure. Contraception. 2009;79:334–338
  3. Weshtoff C, Reape K, Shu H. Impact of body weight on observed pregnancy rates with a low-dose estrogen, 91-day extended regimen oral contraceptive. Contraception. 2009;80:196
  4. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215–231
  5. Cheymol G. Drug pharmacokinetics in the obese. Fund Clin Pharmacol. 1988;2:239–256
  6. Huber J. Pharmacokinetics of Implanon: an integrated analysis. Contraception. 1998;58:85S–90S
  7. Rahimy MH, Cromie MA, Hopkins NK, Tong DM. Lunelle(TM) monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. Contraception. 1999;60:201–208
  8. Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001;64:43–49
  9. Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception. 2009;80:119–127
  10. World Health Organization Department of Reproductive Health and Research . Medical eligibility criteria for contraceptive use. In: 3rd ed.. Geneva: World Health Organization; 2004;
  11. Price TM, Dupuis RE, Carr BR, Stanczyk FZ, Lobo RA, Droegemueller W. Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol. 1993;168:1400–1406
  12. Stanczyk FZ, Hiroi M, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. Contraception. 1975;12:279–298
  13. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception. 2008;78:4–9
  14. Westhoff C, Torgal A, Mayeda ER, Lerner J, Paik M. Ovarian suppression during oral contraceptive use in normal-weight and obese women. Contraception. 2009;80:210

PII: S0010-7824(10)00017-X

doi: 10.1016/j.contraception.2010.01.016

Contraception
Volume 81, Issue 6 , Pages 474-480 , June 2010

Article Tools

* Image Usage & Resolution